Key clinical point:
Major finding: Median overall survival for patients with 0-1, 2-3, and 4 or more factors was 19.6, 5.9, and 2.8 months in the development cohort, and 19.4, 7.2 and 2.6 months in the validation cohort, respectively.
Data source: A study among patients given atezolizumab for advanced urothelial carcinoma with a development cohort (310 patients from the phase 2 IMvigor210 trial) and a validation cohort (95 patients from the phase 1 PCD4989g trial).
Disclosures: Dr. Pond disclosed that an immediate family member is an employee of Roche Canada. Genentech provided data for this study.
Source: Pond GR et al. GU Cancers Symposium Abstract 413
Read the full article.
Pond GR et al. GU Cancers Symposium Abstract 413
This Week's Must Reads
How do you pronounce that drug name?, Frank D. JAMA Intern Med. 2018;178(3):319-320. doi:10.1001/jamainternmed.2017.7898
'Glass ceiling' extends to biomedical industry payments, Tringale K and Hattangadi-Gluth J. JAMA Intern Med. 2018;178(3):421-423. doi:10.1001/jamainternmed.2017.7445
Mining social media to detect adverse drug reactions to newly-approved drugs, Ransohoff J et al. JAMA Oncology March 1, 2018. doi:10.1001/jamaoncol.2017.5688
Insurance type linked to cancer care delays, Wharam et al. J Clin Oncol. 2018 Feb 28. doi: 10.1200/JCO.2017.75.2501.
Intervention boosted the rate of colorectal cancer screening, Source: Miller, D et al. Ann Inter Med 2018. DOI: 10.7326/M17-2315
Must Reads in Renal Cell Carcinoma
Six factors predict urothelial cancer response, Pond GR et al. GU Cancers Symposium Abstract 413
Combo bests single therapy in metastatic RCC, Motzer RJ et al. GU Cancers Symposium Abstract 578
Chemo is best course in resected urothelial disease, Birtle A et al. Genitourinary Cancers Symposium. Abstract 407.
Selecting chemoradiation in bladder cancer, Coen, J. et al, 2018 Genitourinary Cancers Symposium, Abstract 408.
When to choose surgery or surveillance in RCC, Hakimi A et al. J Urol. 2018 Feb 26 doi: 10.1016/j.juro.2018.02.3087.